Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34626478.
- Also identified by DOI 10.1093/cid/ciab898.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We analyzed June 2021 Medicare Advantage/Part D enrollment and formulary data. Oral vancomycin and fidaxomicin, frontline Clostridioides difficile treatments, were in the formulary for 100% (42314676 of 42314676) and 84.1% (35598385 of 42314676) of enrollees, respectively. However, they were broadly accessible (formulary, unrestricted, tier 1 or 2) to only 14.4% (6104348 of 42314676) and 1.1% (483004 of 42314676), respectively.
Medical subject headings
- Clostridioides difficile
- Clostridium Infections